Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
39 participants
INTERVENTIONAL
2017-03-02
2017-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
NCT02842151
Reduction of Corneal Astigmatism With Toric Intraocular Lens Implantation in Congenital Cataract
NCT02040129
Astigmatism Management in Cataract Surgery With the AcrySof Toric Intraocular Lens
NCT01075542
Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software
NCT04495829
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
NCT01279031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRS
First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
Cataract Refractive Suite (CRS)
Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
Standard manual technique
Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Manual
First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
Cataract Refractive Suite (CRS)
Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
Standard manual technique
Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract Refractive Suite (CRS)
Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
Standard manual technique
Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Planned cataract surgery and implantation of ReSTOR +2.5 D multifocal intraocular lens (IOL) in both eyes;
* Clear intraocular media, other than cataract, in study eye(s);
* Willing and able to complete all required postoperative visits;
* Able to comprehend and sign a statement of informed consent;
Exclusion Criteria
* History of or current severe dry eyes, retinal/uveal pathology or concurrent ocular disease;
* Previous intraocular or corneal refractive surgery, corneal transplant, or retinal detachment;
* Any inflammation or edema (swelling) of the cornea;
* Pregnant;
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon, a Novartis Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sr. Clinical Manager, GCRA
Role: STUDY_DIRECTOR
Alcon, A Novartis Division
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alcon Investigative Site
Panama City, Florida, United States
Alcon Investigative Site
Stillwater, Minnesota, United States
Alcon Investigative Site
Hurst, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTK246-P001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.